Research & Development
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Deal Snapshot: Other major players have made headway in bispecifics for prostate cancer, while Jemincare’s drug is the latest China-developed technology to head westward.
Brexpiprazole could be approved as soon as 2023, and Lundbeck has pledged to support its uptake with investment in its salesforce and direct-to-consumer advertising.
AbbVie is to terminate the clinical development of lemzoparlimab for myelodysplastic syndrome and acute myeloid leukemia and will also reduce the size of its 2020 deal with originator I-Mab by $445m, in the latest blow to the Chinese firm.
The Phase III PIONEER study in indolent systemic mastocytosis met the primary endpoint, but the magnitude of benefit came up short of analysts’ expectations.
The Paris-headquartered company has thrown in the towel on its oral SERD, leaving Roche, Eli Lilly and AstraZeneca to pursue Menarini in the field.
One of the architects of AstraZeneca’s burgeoning cancer portfolio, oncology R&D head Susan Galbraith is making sure the firm does not rest on its laurels. She talked to Scrip about what’s coming next from the UK major’s cancer pipeline.
Following an investigator-initiated clinical development program demonstrating its value, Japan has granted reimbursement to UCB's anticonvulsant E Keppra for status epilepticus, pending what appears to be the formal approval globally in this indication.
When a loss-making rare disease biotech company’s product takes on Pfizer in the same indication but without the benefit of superior data, pharmaceutical marketing lessons will be learnt.
The final Phase III readout for Ilaris (canakinumab) in NSCLC, this time in the adjuvant setting, missed the primary endpoint. One more lung cancer trial is under way, a Phase II neoadjuvant study.
Analysts said that while the Phase III survival data could lead to Trodelvy’s FDA approval, it still could face competitive headwinds from AstraZeneca/Daiichi Sankyo’s Enhertu.
Viridian says Phase I/II data for its thyroid eye disease candidate outperforms Horizon’s Tepezza on multiple measures. Company plans quick advancement into Phase III for VRDN-001.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.